UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist

Drugs in R&D, 2023-12, Vol.23 (4), p.453-464

2023

Volltextzugriff (PDF)

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

Journal of clinical pharmacology, 2018-12, Vol.58 (12), p.1533-1540

2018

Volltextzugriff (PDF)

A Simplified PBPK Modeling Approach for Prediction of Pharmacokinetics of Four Primarily Renally Excreted and CYP3A Metabolized Compounds During Pregnancy

The AAPS journal, 2013-10, Vol.15 (4), p.1012-1024

2013

Volltextzugriff (PDF)

adenosine nucleoside inhibitor of dengue virus

Proceedings of the National Academy of Sciences - PNAS, 2009-12, Vol.106 (48), p.20435-20439

2009

Volltextzugriff (PDF)

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4090-4110

2011

Volltextzugriff (PDF)

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4127-4157

2011

Volltextzugriff (PDF)

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results

European journal of pharmaceutical sciences, 2017-01, Vol.96, p.610-625

2017

Volltextzugriff (PDF)

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

CPT: pharmacometrics and systems pharmacology, 2019-11, Vol.8 (11), p.777-791

2019

Volltextzugriff (PDF)

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

Drug metabolism and disposition, 2009-03, Vol.37 (3), p.536-544

2009

Volltextzugriff (PDF)

Regional Characteristics of Long-Term Variability of Summer Precipitation in the Poyang Lake Basin and Possible Links with Large-Scale Circulations

Atmosphere, 2020-10, Vol.11 (10), p.1033

2020

Volltextzugriff (PDF)

Model‐Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients

CPT: pharmacometrics and systems pharmacology, 2020-04, Vol.9 (4), p.230-237

2020

Volltextzugriff (PDF)

Inhibition of Dengue Virus RNA Synthesis by an Adenosine Nucleoside

Antimicrobial Agents and Chemotherapy, 2010-07, Vol.54 (7), p.2932-2939

2010

Volltextzugriff (PDF)

Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability

Biopharmaceutics & drug disposition, 2012-12, Vol.33 (9), p.536-549

2012

Volltextzugriff (PDF)

Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions

Cancer chemotherapy and pharmacology, 2012-06, Vol.69 (6), p.1567-1582

2012

Volltextzugriff (PDF)

Utility of Physiologically Based Modeling and Preclinical In Vitro/In Vivo Data to Mitigate Positive Food Effect in a BCS Class 2 Compound

AAPS PharmSciTech, 2013-09, Vol.14 (3), p.1255-1266

2013

Volltextzugriff (PDF)

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach

Journal of pharmaceutical sciences, 2011-10, Vol.100 (10), p.4111-4126

2011

Volltextzugriff (PDF)

Physiologically based pharmacokinetic modeling for assessing the clinical drug–drug interaction of alisporivir

European journal of pharmaceutical sciences, 2014-10, Vol.63, p.103-112

2014

Volltextzugriff (PDF)

Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs

Drug metabolism and disposition, 2009-03, Vol.37 (3), p.545-554

2009

Volltextzugriff (PDF)

Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug–Drug Interaction Potential of Siponimod With Physiologically‐Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations

Clinical pharmacology and therapeutics, 2019-11, Vol.106 (5), p.1113-1124

2019

Volltextzugriff (PDF)

Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol–polysorbate 80 solid dispersion carrier system

Journal of pharmaceutical sciences, 2004-05, Vol.93 (5), p.1165-1175

2004

Volltextzugriff (PDF)

Abstract 6360: In vivo antitumor efficacy evaluation of ASC63, an oral small molecule PD-L1 inhibitor, in a humanized mouse tumor model

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (7_Supplement), p.6360-6360

2023

Volltextzugriff (PDF)

IV-IVC considerations in the development of immediate-release oral dosage form

Journal of pharmaceutical sciences, 2005-07, Vol.94 (7), p.1396-1417

2005

Volltextzugriff (PDF)

Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds

Journal of pharmaceutical sciences, 2015-09, Vol.104 (9), p.2795-2806

2015

Volltextzugriff (PDF)

Abstract 5529: In vivo efficacy evaluation of ASC61, an oral PD-L1 inhibitor, in two tumor mouse models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5529-5529

2022

Volltextzugriff (PDF)

Abstract 5466: Efficacy of ASC60, an oral fatty acid synthase inhibitor, in two tumor mouse models

Cancer research (Chicago, Ill.), 2022-06, Vol.82 (12_Supplement), p.5466-5466

2022

Volltextzugriff (PDF)

1 – 25 von 6.264

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(4.814)
Mit Volltextzugriff
(4.279)

Publikationsform

6 weitere anzeigen...

Weniger anzeigen...

Sprache

9 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ASC42, a Novel Farnesoid X Receptor Agonist

Clinical Pharmacokinetic and Pharmacodynamic Overview of Nilotinib, a Selective Tyrosine Kinase Inhibitor

A Simplified PBPK Modeling Approach for Prediction of Pharmacokinetics of Four Primarily Renally Excreted and CYP3A Metabolized Compounds During Pregnancy

adenosine nucleoside inhibitor of dengue virus

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: Comparative assessement of prediction methods of human clearance

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the physiologically‐based pharmacokinetic modeling approach

IMI – Oral biopharmaceutics tools project – Evaluation of bottom-up PBPK prediction success part 2: An introduction to the simulation exercise and overview of results

Applications of Quantitative Systems Pharmacology in Model‐Informed Drug Discovery: Perspective on Impact and Opportunities

Absorption, metabolism, and excretion of [14C]vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in humans

Regional Characteristics of Long-Term Variability of Summer Precipitation in the Poyang Lake Basin and Possible Links with Large-Scale Circulations

Model‐Informed Drug Development for Everolimus Dosing Selection in Pediatric Infant Patients

Inhibition of Dengue Virus RNA Synthesis by an Adenosine Nucleoside

Nilotinib preclinical pharmacokinetics and practical application toward clinical projections of oral absorption and systemic availability

Novel physiologically based pharmacokinetic modeling of patupilone for human pharmacokinetic predictions

Utility of Physiologically Based Modeling and Preclinical In Vitro/In Vivo Data to Mitigate Positive Food Effect in a BCS Class 2 Compound

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 4: Prediction of plasma concentration–time profiles in human from in vivo preclinical data by using the Wajima approach

Physiologically based pharmacokinetic modeling for assessing the clinical drug–drug interaction of alisporivir

Disposition of vildagliptin, a novel dipeptidyl peptidase 4 inhibitor, in rats and dogs

Prediction of the Impact of Cytochrome P450 2C9 Genotypes on the Drug–Drug Interaction Potential of Siponimod With Physiologically‐Based Pharmacokinetic Modeling: A Comprehensive Approach for Drug Label Recommendations

Development of clinical dosage forms for a poorly water soluble drug I: Application of polyethylene glycol–polysorbate 80 solid dispersion carrier system

Abstract 6360: In vivo antitumor efficacy evaluation of ASC63, an oral small molecule PD-L1 inhibitor, in a humanized mouse tumor model

IV-IVC considerations in the development of immediate-release oral dosage form

Prospective Predictions of Human Pharmacokinetics for Eighteen Compounds

Abstract 5529: In vivo efficacy evaluation of ASC61, an oral PD-L1 inhibitor, in two tumor mouse models

Abstract 5466: Efficacy of ASC60, an oral fatty acid synthase inhibitor, in two tumor mouse models

Suchergebnisse filtern